SOURCE: Clenergen Corporation Limited (UK)

September 09, 2009 08:34 ET

Clenergen Corporation (OTCBB : CRGE) Secures Exclusive License to Use Proprietary Plant Adaption Technology

LONDON--(Marketwire - September 9, 2009) -

Clenergen Corporation CEO Mark Quinn today announced the acquisition of an exclusive intellectual property license for use in India and Sri Lanka from Star Biotechnology Ltd which will give his company immediate access to the technology and know-how required to increase the rate of biomass production and so assist the generation of clean electricity through gasification.

"This is a significant source of plant science and expertise for Clenergen and will literally accelerate the development of our ambitions in the field. We have been working with the science team for the past six months and I am glad to have now reached this milestone",

Said Mr. Quinn today.

Using mother strains of Paulownia originating from Australia, the Polyploidy Technology Plant Adaption Process (PTPAP) will be applied to produce an entirely new species of fast growing tree, specifically cultivated to thrive in the climate and soils of land leased by Clenergen in India and Sri Lanka. It is projected that the application of PTPAP will result in up to a 40% increase in the growth of saplings within two years from planting. On granting the license to Clenergen, Star Biotechnology's Stephen Von Peltz commented,

"This is an exciting new license for an exciting, young company and we are proud to supply the necessary knowledge and expertise required by Clenergen and their partners"

As part of fifteen year license, Arbour Technologies Ltd of Queensland, Australia has also been engaged to provide research, development and agronomy management for the cultivation of this biomass feedstock for gasification and the production of clean electricity by Clenergen.

Speaking of their involvement, Arbour Technologies' Malcolm Lamont said,

"We look forward to working on this innovative project and with all of the Clenergen team"

Within six months of the exclusive license being effective, 18,000 polyploidy Paulownia saplings and 6000 parent (non-polyploidy) saplings will be ready to plant and support clean electricity projects. The Company's subsidiary, Clenergen India Private Limited, has executed a 71 MW Power Purchase Agreement with the Power Trading Corporation of India and is currently in the first phase of development in the Tamilnadu region of India. This facility when built, will be able to utilize the biomass from the saplings to convert into electricity.

Notes for Editors

Clenergen Corporation is a publicly listed company on the OTC stock market (symbol CRGE). Clenergen develops Clean Energy Generation projects to address the requirement for renewable and sustainable supplies of electricity. Clenergen installs and operates Distributed Environmental Power Systems (DEPS) and applies plant science to the cultivation of proprietary biomass feedstocks in order to provide sustainable supplies of clean energy to regional, independent clients and national grids.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to our ability to accelerate the cultivation of proprietary feedstock and to establish our company as one of the leading biomass power generating companies globally.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with clean technologies; changes in the operating costs and changes in economic conditions and conditions in clean technologies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our current and periodic reports filed from time-to-time with the Securities and Exchange Commission.

- END -

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • Contact:

    Jessica Hatfield
    Communications Director
    Clenergen Corporation
    Tel: 0044 (0)207 739 0028
    Fax: 0044 (0)207 657 3275